Danaher stock has delivered a decline of 26.6% over the past 5 years, yet current checks suggest the shares now trade near an intrinsic value estimate while still screening expensive on traditional multiples. The result is a company with mixed long term performance and a low overall value score, but without a clear discount on most valuation yardsticks.
-
Over 5 years, Danaher shares are down 26.6%, which may lead some investors to question whether the recent pricing now already reflects that weaker stretch.
-
New product approvals at subsidiaries such as Masimo can support expectations for future cash flows. However, any setback in bringing these technologies into routine clinical use may limit how much investors are willing to pay for that potential.
-
Across broader valuation checks, Danaher earns a low value score of 2 out of 6, which suggests the stock leans expensive rather than offering an obvious bargain.
The issue now is whether Danaher's current price, with the stock fairly valued on a Discounted Cash Flow (DCF) view but overvalued on market multiples, offers enough potential to justify the risk of owning it at this level.
Compare Danaher's mixed valuation picture with other high quality companies by scanning 54 high quality undervalued stocks that share solid fundamentals and appear to have more room in their pricing.
Does Danaher Look Fairly Valued on Cash Flow?
The Discounted Cash Flow (DCF) model values Danaher by projecting future cash the business can return to shareholders and then discounting those amounts back to today. On this view, Danaher generated about $5.3b of free cash flow over the last twelve months, with the model using cash flow growth assumptions rather than assuming a shrinking business. That pattern supports an estimated intrinsic value of about $228 per share.
Compared with the current share price, this DCF outcome suggests that Danaher stock appears roughly 7.9% undervalued on cash flow assumptions alone. The recent FDA 510(k) clearance for Masimo's Root with LiDCO and the LiDCO sensor may help support those long term cash flow expectations, because it adds another cleared product platform within the group.
On the DCF model, Danaher appears roughly fairly valued, with only a modest tilt toward being undervalued at recent prices.
Danaher is fairly valued according to our Discounted Cash Flow (DCF) , but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act.
Has Danaher Run Too Far on Earnings?
P/E is usually the cleanest way to compare Danaher with other Life Sciences stocks because earnings are a core focus for many investors in this sector. Danaher currently trades on a P/E of 37.0x. That is slightly below the wider Life Sciences industry average of 37.5x, yet above the peer group average of 33.1x.
The fair P/E ratio, based on factors such as Danaher's sector, size and risk profile, is estimated at 31.8x. The gap between this and the current 37.0x suggests the stock screens overvalued on earnings, even though it is roughly in line with the broader industry. For investors, that means you are paying a premium to the peer group for each dollar of Danaher's earnings today.
On the P/E multiple, Danaher stock appears overvalued relative to what the model suggests would be a more reasonable earnings-based price.
See what the numbers say about this price — find out in our valuation breakdown.
The Danaher Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where Danaher's valuation puzzle leaves off. They spell out which assumptions on Danaher's future growth, margins and earnings would need to hold for the stock to be worth significantly more or less than it is today. Each one ties a fair value estimate to a specific story about the company's potential catalysts and risks so you can judge over time which version of events appears to be unfolding on the Community page.
Add your voice to the Simply Wall St community with a number driven Narrative on Danaher that sets out your case and the key metrics you are watching. This is a chance to put a clear view on whether developments such as Masimo's FDA 510(k) clearance for Root with LiDCO and the Masimo LiDCO sensor support Danaher's current pricing, and to track how your thesis holds up as new information arrives.
Do you think there's more to the story for Danaher? Head over to our Community to see what others are saying!
The Bottom Line
For Danaher, the Discounted Cash Flow (DCF) work suggests the intrinsic value is close to the current share price with only a modest discount. Market multiples tell a different story and point to an overvalued stock relative to peers and to a fair P/E estimate. That split reflects a focus on cash flow durability on one side and on earnings expectations and sentiment on the other, while broader checks still lean weak. The key question from here is whether Danaher can deliver the cash flow and earnings path that keeps investors comfortable paying a premium multiple.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include DHR .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
